Physician profile
Layne Keliiokalam Kamalu
NPI 1104987916
$11,864.26
in general payments reported to CMS, 2019-2025
27 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,535 · 2020: $80.94 · 2021: $1,829 · 2022: $1,172 · 2023: $1,125 · 2024: $1,606 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,900 · Food and Beverage: $1,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,900.00 |
| Food and Beverage | $1,347.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $8,550.00 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,225.05 | 2021 | |
| Indivior INC. | $721.21 | 2019-2025 | Sublocade |
| Abbvie INC. | $282.47 | 2022-2025 | |
| Novo Nordisk INC | $142.91 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Braeburn INC. | $142.37 | 2023-2025 | Brixadi |
| Exact Sciences Corporation | $133.19 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $103.98 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $57.77 | 2023 | Quviviq |
| Neuronetics, INC. | $46.78 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $46.11 | 2022 | |
| Pfizer INC. | $44.15 | 2023 | |
| Titan Pharmaceuticals, INC. | $42.02 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $37.28 | 2022-2023 | Keveyis |
| Lilly USA, LLC | $36.84 | 2024-2025 | Mounjaro, Zepbound |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $33.55 | 2024-2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $30.10 | 2024 | Voquezna |
| Lucid Diagnostics INC. | $26.87 | 2022-2023 | |
| Genzyme Corporation | $23.38 | 2023 | |
| Biogen, INC. | $20.69 | 2025 | Skyclarys |
| Ultragenyx Pharmaceutical INC. | $20.33 | 2022 | |
| Dexcom, INC. | $19.60 | 2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $19.16 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $17.88 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $14.82 | 2023 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $14.72 | 2020 | |
| Eisai INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layne Kamalu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.